Mast cells and inflammatory bowel disease

Baumgart, 2012, Crohn's disease, Lancet, 380, 1590, 10.1016/S0140-6736(12)60026-9 Ordas, 2012, Ulcerative colitis, Lancet, 380, 1606, 10.1016/S0140-6736(12)60150-0 Abraham, 2010, Mast cell-orchestrated immunity to pathogens, Nat Rev Immunol, 10, 440, 10.1038/nri2782 Sayed, 2007, Mast cells as modulators of T-cell responses, Immunol Rev, 217, 53, 10.1111/j.1600-065X.2007.00524.x Bischoff, 2009, Physiological and pathophysiological functions of intestinal mast cells, Semin Immunopathol, 31, 185, 10.1007/s00281-009-0165-4 Reber, 2015, Potential effector and immunoregulatory functions of mast cells in mucosal immunity, Mucosal Immunol, 8, 444, 10.1038/mi.2014.131 Cheng, 2013, Perivascular mast cells dynamically probe cutaneous blood vessels to capture immunoglobulin E, Immunity, 38, 166, 10.1016/j.immuni.2012.09.022 Gurish, 2012, Developmental origin and functional specialization of mast cell subsets, Immunity, 37, 25, 10.1016/j.immuni.2012.07.003 Weidner, 1993, Heterogeneity of mast cells at multiple body sites. Fluorescent determination of avidin binding and immunofluorescent determination of chymase, tryptase, and carboxypeptidase content, Pathol Res Pract, 189, 156, 10.1016/S0344-0338(11)80086-5 Gilfillan, 2006, Integrated signalling pathways for mast-cell activation, Nat Rev Immunol, 6, 218, 10.1038/nri1782 Bischoff, 2007, Human mast cells, bacteria, and intestinal immunity, Immunol Rev, 217, 329, 10.1111/j.1600-065X.2007.00523.x Gelbmann, 1999, Strictures in Crohn's disease are characterised by an accumulation of mast cells colocalised with laminin but not with fibronectin or vitronectin, Gut, 45, 210, 10.1136/gut.45.2.210 Andoh, 2006, Immunohistochemical study of chymase-positive mast cells in inflammatory bowel disease, Oncol Rep, 16, 103 Vivinus-Nebot, 2014, Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation, Gut, 63, 744, 10.1136/gutjnl-2012-304066 Kurashima, 2012, Extracellulat ATP mediates mast cell-dependent intestinal inflammation through P2X7 purinoceptors, Nat Commun, 3, 1034, 10.1038/ncomms2023 Raithel, 1999, Effect of substance P on histamine secretion from gut mucosa in inflammatory bowel disease, Scand J Gastroenterol, 34, 496, 10.1080/003655299750026236 Raithel, 2001, Release of mast cell tryptase from human colorectal mucosa in inflammatory bowel disease, Scand J Gastroenterol, 36, 174, 10.1080/003655201750065933 Winterkamp, 2002, Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease, Am J Gastroenterol, 97, 3071, 10.1111/j.1572-0241.2002.07028.x te Velde, 2007, Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease, Inflamm Bowel Dis, 13, 325, 10.1002/ibd.20079 Rijnierse, 2007, Mast cells and nerves tickle in the tummy: implications for inflammatory bowel disease and irritable bowel syndrome, Pharmacol Ther, 116, 207, 10.1016/j.pharmthera.2007.06.008 Matsukawa, 2015, Ceramide-CD300f binding suppresses experimental colitis by inhibiting ATP-mediated mast cell activation, Gut Nakahashi-Oda, 2012, Apoptotic cells suppress mast cell inflammatory responses via the CD300a immunoreceptor, J Exp Med, 209, 1493, 10.1084/jem.20120096 Vergnolle, 2015, Protease inhibition as new therapeutic strategy for GI disease, Gut Vergnolle, 2004, A role for proteinase-activated receptor-1 in inflammatory bowel diseases, J Clin Invest, 114, 1444, 10.1172/JCI21689 Hamilton, 2011, Essential role for mast cell tryptase in acute experimental colitis, Proc Natl Acad Sci U S A, 108, 290, 10.1073/pnas.1005758108 Hansbro, 2014, Importance of mast cell Prss31/transmembrane tryptase/tryptase-gamma in lung function and experimental chronic obstructive pulmonary disease and colitis, J Biol Chem, 289, 18214, 10.1074/jbc.M114.548594 Hoving, 2012, B cells that produce immunoglobulin E mediate colitis in BALB/c mice, Gastroenterology, 142, 96, 10.1053/j.gastro.2011.09.044 Rijnierse, 2010, Ig-free light chains play a crucial role in murine mast cell-dependent colitis and are associated with human inflammatory bowel diseases, J Immunol, 185, 653, 10.4049/jimmunol.0901129 Bernstein, 2010, A prospective population-based study of triggers of symptomatic flares in IBD, Am J Gastroenterol, 105, 1994, 10.1038/ajg.2010.140 Soderholm, 2001, Stress and gastrointestinal tract. II. Stress and intestinal barrier function, Am J Physiol Gastrointest Liver Physiol, 280, G7, 10.1152/ajpgi.2001.280.1.G7 Wallon, 2011, Eosinophils express muscarinic receptors and corticotropin-releasing factor to disrupt the mucosal barrier in ulcerative colitis, Gastroenterology, 140, 1597, 10.1053/j.gastro.2011.01.042 Qiu, 1999, The role of CD4+ lymphocytes in the susceptibility of mice to stress-induced reactivation of experimental colitis, Nat Med, 5, 1178, 10.1038/8328 Zheng, 2009, Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestine, Gut, 58, 1473, 10.1136/gut.2009.181701 Tremaine, 2002, Treatment of mildly to moderately active ulcerative colitis with a tryptase inhibitor (APC 2059): an open-label pilot study, Aliment Pharmacol Ther, 16, 407, 10.1046/j.1365-2036.2002.01194.x